

# **CURRICULUM VITAE**

***JONATHAN PINKNEY BSc, MB BS, MD, FRCP***

**PROFESSOR OF  
ENDOCRINOLOGY AND DIABETES**

**PENINSULA SCHOOLS OF MEDICINE  
AND DENTISTRY,  
UNIVERSITY OF PLYMOUTH**

**HONORARY CONSULTANT PHYSICIAN  
IN ENDOCRINOLOGY, DIABETES AND GENERAL  
INTERNAL MEDICINE PLYMOUTH HOSPITALS  
NHS TRUST**

**HONORARY CONSULTANT IN WEIGHT  
MANAGEMENT, PLYMOUTH COMMUNITY  
HEALTHCARE TRUST**

## **SYNOPSIS**

I am a Consultant Physician at Plymouth Hospitals NHS Trust, and Professor of Endocrinology and Diabetes at the Peninsula Schools of Medicine and Dentistry. I have special interests in diabetes, endocrinology and obesity. I am the consultant lead for the Plymouth Weight Management Clinic and I am a recognised authority in the field of obesity.

I have many years of experience in the preparation of expert witness reports in the fields of diabetes, endocrinology, acute general medicine, and in the specialty area of obesity. My work has encompassed expert reports for prosecution and defence, joint reports, and court appearance.

**PERSONAL DETAILS:**

**Jonathan Henley Pinkney BSc, MB BS, MD, FRCP.**

**Born 18.10.60, Bristol, UK.**

**General Medical Council:** Full registration 3078220.

**Medical Defence Union:** Membership 1955141.

**CCST 1997:** Endocrinology, Diabetes and General Internal Medicine.

**Home address:**

Polwithan,  
39, Falmouth Rd.,  
Truro,  
Cornwall TR1 2BL.

Telephone: 01872 271806

Mobile: 0788 4376647

**Current position:**

**Professor of Endocrinology and Diabetes, Peninsula Schools of Medicine and Dentistry, University of Plymouth.**

**Honorary Consultant Physician in Medicine (Diabetes, Endocrinology and General Internal Medicine), Plymouth Hospitals NHS Trust.**

Peninsula School of Medicine and Dentistry,  
Centre for Clinical Trials and Population Studies,  
Room N6, Plymouth Science Park, Phase 1,  
1, Davy Road,  
Plymouth PL6 8BX

University Medicine,  
Level 7,  
Derriford Hospital  
Plymouth PL6 8DH

E-mail: [Jonathan.Pinkney@plymouth.ac.uk](mailto:Jonathan.Pinkney@plymouth.ac.uk)

**EDUCATION:****(i) UNDERGRADUATE EDUCATION:**

- 1979-82**      **University of London, King's College.**  
**1982**          **BSc. Neurosciences. (2/1).**  
**1983-85**      **MB BS. Charing Cross and Westminster School of Medicine, University of London.**

**(ii) POSTGRADUATE APPOINTMENTS :**

- 8/85-1/86**      **House Physician.** General Medicine and Medical Oncology. Poole General Hospital, Dorset.  
**2/86-7/86**      **House Surgeon.** General and gastrointestinal surgery. Royal Surrey County Hospital, Guildford.  
**8/86-8/88**      **Senior House Officer** training scheme in medicine. William Harvey Hospital, Ashford, Kent.  
**1988-1991**      **Registrar in Medicine.** Rotational training scheme. Homerton & St Bartholomew's Hospitals, London.  
**1991-1992**      **Research Assistant.** Department of Diabetes and Metabolism, St Bartholomew's Hospital School of Medicine.  
**1992**            **Locum Senior Registrar in Diabetes and Endocrinology,** Middlesex Hospital, London.  
**1992**            **Locum Senior Registrar in Diabetes and Endocrinology,** Addenbrooke's Hospital Cambridge.  
**1992-1995**      **Clinical Lecturer,** honorary registrar in medicine. University College London School of Medicine, Division of Medicine, Department of Diabetes and Endocrinology.  
**1995-1998**      **Lecturer in Endocrinology and Diabetes (Honorary Senior Registrar in Medicine).** University of Bristol, Bristol Royal Infirmary and Southmead Hospital Bristol.  
**1998**            **Wellcome Travelling Fellow.** Molecular Biology Laboratory, Pennington Biomedical Research Center. Louisiana State University, Baton Rouge.  
**1999-2001**      **Senior Lecturer in Medicine and Honorary Consultant Physician** (temporary position), University of Bristol Department of Medicine, Department of Diabetes and Endocrinology and Centre for Neurosciences, Bristol Royal Infirmary and **Locum Consultant Physician, Diabetes and Endocrinology** Weston General Hospital, North Somerset.  
**2001-2005**      **Senior Clinical Lecturer** in Medicine, University of Liverpool.  
**Honorary Consultant Physician** in Endocrinology, Diabetes and General Internal Medicine, Aintree Hospitals NHS Trust, Liverpool.  
**2005-2010**      **Consultant Physician,** Diabetes, Endocrinology and Internal Medicine, Royal Cornwall Hospitals NHS Trust Truro, and **Honorary Senior Lecturer,** Peninsula College of Medicine and Dentistry, Universities of Exeter and Plymouth.

**POSTGRADUATE QUALIFICATIONS:**

<b>Member Royal College of Physicians (London)</b>	<b>1988.</b>
<b>MD doctoral thesis, University College London</b>	<b>1997.</b>
<b>Fellow Royal College of Physicians (London)</b>	<b>2003.</b>

### **MEMBERSHIPS OF LEARNED SOCIETIES:**

<b>European Association for the Study of Diabetes</b>	<b>Member</b>
<b>The Endocrine Society.</b>	<b>Member</b>
<b>Pituitary Foundation</b>	<b>Medical Committee</b>
<b>Association for the Study of Obesity</b>	<b>Committee member</b>
<b>National Obesity Forum.</b>	<b>Patron</b>

### **PRINCIPAL RESEARCH INTERESTS:**

- **Pathogenesis of diabetes and its complications.**
- **Managing obesity in patients with diabetes.**
- **Patient-centred care in the treatment of obesity.**
- **Endocrinology and neuroendocrinology of obesity and diabetes.**
- **Childhood origins of metabolic disease and metabolic programming, including new molecular biomarkers (The Earlybird Study)**
- **Health Services Research and acute medical admissions in the NHS (The 3A study)**

### **AWARDS AND RESEARCH INCOME:**

- 1982 Medical Research Council BSc studentship.
- 1994 British Diabetic Association Lilly Simms travel award - IDF, Japan.
- 1995 Medical Research Council Project grant "An investigation of sodium-hydrogen exchange and birthweight". **£46,000** over 12 months.
- 1995 British Heart Foundation Junior Research Fellowship. Department of Clinical Biochemistry, Cambridge University. *[Awarded but not taken up]*.
- 1995 Raymond and Beverley Sackler Postgraduate Fellowship. Cambridge University.
- 1996 United Bristol Hospitals Research Foundation. "Investigation of the effects of IGF-1, insulin and aminoacid deprivation on cell programming". **£15,000** over 12 months.
- 1996 Southmead Hospital Bequests. Studies of hypertension in type-1 diabetes. **£1,200**
- 1996 Southmead Hospital Research Foundation. "Studies on the roles of lipoprotein oxidation, antioxidant vitamins and advanced glycation endproducts in endothelial dysfunction in IDDM". **£4,600** over 12 months.
- 1997 Southmead Hospital Research Foundation. "Studies on the effect of catecholamine infusions on leptin production in lean and obese subjects". **£3,925** over 12 months.
- 1997 Southmead Hospital Research Foundation. "Endothelial function in chronic renal failure and coronary heart disease. **£77,000** over 12 months.
- 1998 Wellcome Trust Travelling Fellowship, Louisiana State University, Pennington Research Center. Novel human uncoupling proteins in human adipose tissue: Gene expression and physiological correlates.

- 1999 81<sup>st</sup> Endocrine Society (San Diego) travel award.
- 1999 Neuroendocrine Charitable Trust. Central effects of IL-6 in energy balance in obesity. **£33,000** over 12 months.
- 2000 Wellcome Trust. Regulation of UCP2 expression and function in white adipose tissue. **£85,000** over 2 years. In collaboration with Dr V. Mohamed-Ali (UCL).
- 2001 Diabetes UK. Cytokine genes in central obesity. £9,980 x 2 years.
- 2002 University of Liverpool Research Development Fund **£4,000**. Regulation of cytokine expression in visceral fat.
- 2002 University of Liverpool Research Development Fund. Body composition, metabolism and cardiovascular disease in rheumatoid arthritis. (Coapplicant. PI = Dr Mpofo).
- 2002 TUBITAK/Nato visiting scholarship for Dr M. Cakir. Sex steroids and cytokine gene expression in visceral fat.
- 2003 Johnson and Johnson. Novel strategies in the nutritional regulation of ghrelin. **£100,000**.
- 2003 Merseyside primary healthcare trust; PhD studentship for Paula Morgan. Epidemiological studies on diabetes and obesity in patients with psychiatric disease.
- 2004 Royal Liverpool and Broadgreen Hospital Trust Research Foundation. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) in diabetic and non-diabetic obesity. (Coapplicant with Dr Ranganath and Dr Halford). **£29,700**.
- 2003 Pharmacia International Endocrine Research Prize. Role of ghrelin in the endocrine adaptation to fasting and feeding. **US\$59,800**.
- 2004 University of Liverpool RDF. Adipokines in partial lipodystrophy (Dunnigan Kobberling Syndrome). **£2,000**.
- 2004 Asthma UK. Benefits of weight loss in obese patients with asthma: mechanical or immunological mechanisms? Wilding J, Calverley P, and Pinkney J. **£98,919**.
- 2006 Pan-Peninsula Diabetes Research network bid (Co-applicant, with RCH as a participating centre). (Between 5 centres).
- 2007 Wellcome Wolfsson CRF bid. Names coapplicant. **£7.8 million**.
- 2009 Cornwall Diabetes Research Trustees **£30,000**. Reducing risk of diabetes in women with Polycystic ovary syndrome
- 2009 Takeda Pharmaceuticals. Adiponectin and insulin resistance **£30,000**
- 2009 Sanofi Aventis. Audit of Cornwall Obesity Service. **£15,000**.
- 2009 Sanofi Aventis. Research on Cornwall obesity clinic. **£37,000**.
- 2011 Duchy research charity: Studies on PCOS. **£30,000**.
- 2010 Diabetes quality of life evidence synthesis. RfPB **£265,000**. **PI Professor Nicky Britten**.
- 2011 Diabetes UK, **£48,000**. The diabetes app challenge: User-led development of smartphone apps for diabetes management. PI.
- 2012 NIHR HS&DR. How can frontline expertise safely reduce avoidable acute admissions? **£429,000**. (Co-PI)
- 2014 Nestle Institute for Health Science. **£302,000**. Childhood origins of metabolic disease: The Plymouth Earlybirds as adults. PI.
- 2015 PenCLAHRC PhD studentship for Daniel Marshall. **£59,000**. Patient-centred care in a community weight management clinic. DOS. Co-supervised by Dr W. Lee and Dr H. Lloyd.
- 2015 Nestle Institute for Health Science. **£26,000**. Additional funding for dietary studies on Earlybirds cohort.
- 2015 Peninsula Medical Foundation. **£12,000**. Childhood origins of metabolic disease. The Plymouth earlybirds as adults.
- 2015 Penclahrc. Part time RA support to develop prioritised research question into full bid.

## **OTHER RESEARCH ACTIVITIES:**

*Diabetes Research Network clinical lead for Cornwall 2005-2010.*

*Manuscript reviewing:* Miscellaneous journals including Diabetologia, Diabetic Medicine, Diabetes Care, Journal of Clinical Endocrinology and Metabolism, Circulation, Clinical Endocrinology, Hypertension, Obesity Research, Obesity Reviews. International Journal of Obesity.

*Reviewing of grants and other research outputs:* NIHR HTA, Diabetes UK, Medical Research Council, Wellcome Trust.

*Postgraduate examining:* I undertake regular examining of MSc, PhD and MD theses, acting as both internal and external examiner.

*Academic mentor – University of Plymouth.* I have undergone training to provide mentoring support for senior academics.

## **RESEARCH SUPERVISION:**

*(i) Current PhD thesis supervision:*

Kathy Redfern.

Dan Marshall.

Buki Ajala (Application in progress))

Anthony Wynne (Application in progress)

*(ii) Previous thesis completions:*

Julie Tomlinson (PhD, PCMD).

Bobby Huda (PhD, University of Liverpool).

Terry Dovey (PhD, University of Liverpool).

D. Deepak (MD, University of Liverpool).

Steven Wong (PhD, University of Liverpool).

## **PREVIOUS THESES EXAMINED**

M.Phil, University of Liverpool

M.Phil, University of Liverpool

MD, University of Manchester

PhD, University of London

PhD, University of Exeter

M.Phil, University of London

MS, PCMD

MS, University of Bristol

PhD, PCMD

MD, PCMD

PhD, University of Plymouth

PhD, University of Plymouth

PhD, University of Bristol

PhD, University of Plymouth  
 PhD, University of Plymouth  
 PhD, University of Liverpool

### **INVITED TALKS:**

Health Services Research Network	2015
Society for Endocrinology	2015
Diabetes UK	2013
Society for Endocrinology	2013
Diabetes UK	2012
World Diabetes Congress, Dubai	2011
Diabetes UK	2011
Italian Bariatric Surgical Society/Diabetes Association	2010
Association of British Clinical Diabetologists	2010
American Association of Clinical Endocrinologists	2010
National Obesity Forum	2010
National Diabetes Forum	2010
International Federation for Surgery for Obesity, Paris	2009
Diabetes UK Plenary APC	2009
National Obesity Forum	2009
Association Clinical Biochemists	2008
Royal Society of Medicine	2008
ASO Conference	2008
ASO regional conference	2008
Pituitary Foundation	2008
Pituitary Foundation	2007
European Microcirculation Society, Amsterdam	2006
Royal Society of Medicine Update on diabetes. RSM, London	2006
Leeds's Nutrition Course Obesity and diabetes. Leeds	2006
Westminster Health Forum	2006
National Obesity Forum National Conference, London	2006
ASO Training Course Liverpool	2006
ASO conference Cornwall,	2006
ASO symposium London	2005
Obesity in Primary Care Symposium, Royal College of Surgeons	2005
All-party parliamentary group on obesity	2005
Pituitary Foundation Annual Conference, University of Edinburgh	2005
Craniopharyngioma and hypothalamic obesity	
Endocrine disease in children	
Parents workshop	
Symposium on Obesity and its Management, Eden Project	2005
ASO Obesity Training Course	2005
Pituitary Foundation Annual Conference, University of Reading	2004
National Obesity Forum	2004
Multiple Endocrine Neoplasia, symposium Belfast	2004



National Conference on Diabetes in Primary Care, London	2004
GlaxosmithKline, London	2004
Diabetes UK, Glasgow	2003
Astra Zeneca	2003
British Dietetic Association, Nottingham	2003
National Obesity Forum, London	2003
Warwick Diabetes Course	2001-2004
ASO Obesity Training Course	2003
Association of British Clinical Diabetologists, London	2002
ASO Obesity Training Course	2002
ASO Obesity Training Course	2001
Abbott Laboratories Taipei	2002
Liverpool Diabetes Symposium	2001
Glaxosmithkline, London	2001
University of Pamplona	2001
Endocrine Society, San Diego	1999

### **CLINICAL EXPERIENCE AND INTERESTS:**

#### **General Internal Medicine, Diabetes and Endocrinology**

My current NHS appointment is as Honorary Consultant Physician in diabetes and endocrinology. I am an experienced physician with strong track records as a Diabetologist, an Endocrinologist, and as a specialist in Obesity. I keep up to date in Continuing Professional Development through the Royal College of Physicians on-line CPD diary system.

#### **Diabetes**

My training and subsequent appointments have encompassed all aspects of diabetes management including both type 1 and type 2 diabetes, paediatric and adolescent diabetes, antenatal diabetes and other medical disorders of pregnancy, diabetic foot disease, nephropathy management, erectile dysfunction, and assessment of potential candidates for pancreas and combined pancreas/kidney transplantation. My previous research interests (MD) led me to acquire an in-depth knowledge of insulin resistance, hypertension and nephropathy in diabetes. In Bristol and Liverpool I developed a research programme in lipotrophic diabetes, and have maintained an additional interest in the various forms of lipodystrophy, their diagnosis and clinical management.

Following initial appointment at consultant level, I was responsible for diabetes care in North Somerset. I was responsible for the development of new diabetes services and education programmes. I ran the North Somerset Local Diabetes Services Advisory Group, and worked closely with primary care groups to improve local screening for retinopathy and foot disease. I provided an emergency foot service, set up a new adolescent diabetic clinic and successfully obtained funding for the introduction of new digital imaging for retinal screening. In conjunction with our diabetes nurse specialists, I introduced a district "diabetes management pack" for North Somerset, in order to promote good practice in primary care diabetes management, and to facilitate the development of primary care diabetes clinics. I introduced protocols for the management of diabetic emergencies and perioperative management of

diabetes. I obtained a grant from the Millenium Commission to develop the IT systems to archive and transmit clinical images for immediate ophthalmological review. I designed and published an internet site for diabetes care in North Somerset as an adjunct to the community diabetes education programme. In Liverpool, once again I was still at the forefront of developing educational activities in primary care, both for professionals and patients. I completed a new website for the diabetes centre.

After moving to Cornwall with my family in 2005, I was again at the forefront of the modernisation of the diabetes services across primary and secondary care. This involved close working with partners at the PCT, in primary care, and service users. I have worked with public health and commissioning partners to help establish improvements to the diabetic retinal screening service and implement a new diabetic hot foot clinic. This modernisation saw introduction of a modern diabetes in-patient team and a full range of specialist diabetes services in the county. We also developed new protocols and pathways for treatment and spent a lot of time improving education and training around the county.

I was appointed to my current post at Plymouth in April 2010, since when I have once again contributed to developing and running the adult diabetes service, assumed shared responsibility for running the paediatric diabetes transition/adolescent care service, and have contributed to support the acute diabetic foot service. In summary, in all the centres where I have worked as a diabetologist, I have made significant contributions to the development of diabetes services and improvement of patient care. In 2016 I organised a first clinical update meeting on diabetes in East Cornwall – an area with previously neglected diabetes service development.

## **Endocrinology**

I am an endocrinologist, with experience with disorders of the pituitary and hypothalamus, adrenals, thyroid, disorders of calcium homeostasis and bone, as well as gender disorders. My interests and expertise in neuroendocrinology is recognised nationally, as I am a member of the Medical Committee of the Pituitary Foundation. I have strongly supported this organisation for many years, contributing to annual conferences and the development of patient literature. Endocrine abnormalities in obese patients have been one of my specific interests, and a common reason for referral for my opinion. I have a national and international reputation for my special clinical interests in obesity, hypothalamic and other endocrine aspects of obesity. I set up in the North West a joint medical-surgical clinic specifically for families and patients with Multiple Endocrine Neoplasia, in order particularly to address issues of genetic counselling and screening of affected families. This clinic mainly dealt with families with MEN type 1, but also assessed other patients with endocrine tumours or other unusual or suspicious family histories. My work with a clinic for MEN attracted national interest from colleagues and patient groups. I was invited to be a trustee and then patron of the Association for Multiple Endocrine Neoplasia Disorders (AMEND). In Cornwall I was at the forefront of modernising the endocrine service. This included the establishment of an endocrine specialist nurse post and the provision of a full range of Pituitary Foundation support literature in the clinic. Protocols were modernised and important aspects of practice were audited. A variety of special multidisciplinary services set up, including a thyroid clinic and thyroid/parathyroid surgery. We established an improved MDT process to discuss our complex patients with radiology and biochemistry and worked closely with the SW neurosurgery centre at Derriford. I contribute regularly to Society for Endocrinology teaching

programmes in endocrinology and obesity. Since 2013 I have run an update course in endocrinology for primary care, and this has now received sponsorship to become a regular annual event in Plymouth.

## **Obesity**

My special interest in obesity and its treatment arose out of my experiences of the challenges posed by obesity in patients with type-2 diabetes. My clinical and research interests in obesity developed in parallel, and led me to work with Professor George Bray in Louisiana, where I worked on the regulation of uncoupling protein gene expression in human adipose tissue. In 1999 I established a multidisciplinary obesity clinic at Bristol Royal Infirmary. This was an invaluable learning experience for me, demonstrating the many challenges that are faced in establishing medical and surgical obesity management services in the UK, where there have been major needs for training and investment, and some difficulties overcoming historical prejudices and attitudes to obesity. Increasingly, I have been involved in educating local general practitioners and other health professionals on obesity management. I set up a multidisciplinary obesity assessment clinic in Cornwall and played the leading role in the development of these and related clinical services in Cornwall. I succeeded in getting this service formally commissioned from the PCT. I also have extensive experience of selection and management of patients undergoing a variety of different bariatric surgical procedures. As a result I was able to help RCH secure a commissioned service to provide bariatric surgery, which was a major development at RCH. No previous service existed, and so these successes demonstrate that I am a successful and committed team-builder.

In Plymouth I now contribute to the development and delivery of a large weight management service at Plymouth Community Healthcare trust, which received accolades from the CQC following its inspection in 2013. I run an annual symposium on obesity, diabetes and the metabolic syndrome, which attracts a large audience and a programme of world class speakers.

I have contributed for many years to organising and running a well-established annual clinical training course in obesity management on behalf of the Association for the Study of Obesity. I am a national committee member for the ASO and closely involved in planning the scientific conferences for the next few years. I organised the 2010 annual scientific conference programme, which addressed bariatric surgery and the mechanisms by which this type of treatment leads to the amelioration of type 2 diabetes. I have also been a longstanding supporter of the National Obesity Forum of which I am still a patron. I am currently part of the Society for Endocrinology obesity Special Interest Group; this national working party has been establishing a new obesity training programme for trainees in endocrinology. Recently, I was a leading author for a set of new national UK guidelines on the micronutritional management of patients who have undergone bariatric surgery.

**OUTREACH ACTIVITIES:****Endocrinology:**

I have undertaken regular teaching activities for the Pituitary Foundation. This has involved running workshops and lectures for the public on clinical topics in endocrinology. I also answer questions submitted by endocrine patients from around the UK, primarily around the subject of obesity and hypothalamic disease, in which I have a particular interest. In recognition of my work on behalf of endocrine patients and my knowledge of this area I am also a member of the national Medical Committee of the foundation.

I have played an active role in the establishment of a new patient support group for Multiple Endocrine Neoplasia (AMEND – Association for Multiple Endocrine Neoplasia Disorders, UK), for which I have been a trustee and an adviser on issues related to MEN type 1.

**Diabetes and Obesity:**

I have maintained a high profile in the fields of obesity and diabetes. I speak regularly to a wide range of audiences. I have spoken also at Diabetes UK annual patient conferences. I am regularly involved in training and teaching on the subject of managing obesity. I have been actively involved in NOF and ASO initiatives, including media work, and presentations to the All Party Parliamentary Group on Obesity and Westminster Health Forum, to raise the profile of obesity as a health problem that requires recognition and action in the UK. I organised the 2010 ASO conference on bariatric surgery, and was part of the organising committee for the successful UK bid to host the 2013 European Congress on Obesity.

**MEDICOLEGAL WORK:**

I undertake the preparation of occasional medicolegal reports in the fields of diabetes, endocrinology and obesity and expert advisory work for the General Medical Council.

**TEACHING AND EXAMINING:****Undergraduate clinical teaching:**

<b>1988-1991</b>	<b>St Bartholomew's Hospital Medical College.</b>
<b>1992-95</b>	<b>University College London Medical School.</b>
<b>1995-2000</b>	<b>University of Bristol.</b>
<b>2001-2005</b>	<b>University of Liverpool.</b>
<b>2005-2012</b>	<b>Universities of Exeter &amp; Plymouth, PCMD.</b>
<b>2012-present</b>	<b>University of Plymouth, PSMD.</b>

**Undergraduate final MB examining:**

**2001-2005** University of Liverpool.  
**2005-2012** Universities of Exeter & Plymouth, PCMD.  
**2012-present** University of Plymouth, PSMD.

#### **Postgraduate teaching:**

**1992-95** University College London.  
**1995-2000** University of Bristol.  
**2001-2005** University of Liverpool.  
**2005-2012** Universities of Exeter & Plymouth, PCMD.  
**2012-present** University of Plymouth, PSMD.

#### **Traditional teaching experience**

From 1988 onwards I was regularly involved in clinical teaching of students attached to the clinical teams with which I worked. In Bristol I received formal training in teaching methods on the course that was established at that time. In London and Bristol, the courses I was involved in delivering were more of the more traditional types of medical course. These involved me constantly in specialty teaching across a wide range of areas of medicine including cardiology, gastroenterology, rheumatology, respiratory medicine, diabetes and endocrinology. From 1995 onwards, in Bristol, I was more involved in delivery of tutorials and other formal teaching to medical and dental students. Principally from time at Bart's and in Bristol I have extensive experience of running clinical undergraduate examinations.

#### **Experience at University of Liverpool**

After moving to Liverpool, I was involved in more depth in most aspects of undergraduate medical education at the University of Liverpool. I was closely involved in the interviewing and selection process for undergraduate applicants for the course. Liverpool had an undergraduate course similar to that adopted by the PCMD, and I am familiar with the philosophy of much of the PCMD approach. I also received training in PBL-tutoring. My main role in Liverpool included clinical ward-based teaching of students in years 2-5 (ie basic introductions through to more advanced learning), facilitating case discussions amongst students, formal lecturing in diabetes and endocrinology, supervision and assessment of Special Study Modules in diabetes, endocrinology and obesity, exam setting, written exam marking, and clinical examining for the final MB examination. I am also familiar with some of the needs and experiences of students graduating from such a medical course, having mentored a series of house physicians who had graduated from the new course during my time in Liverpool.

#### **Current contributions at Plymouth University / PSMD**

I am clinical teaching lead for our specialty and organize student timetables. I contribute to a range of components of teaching for medical and dental students:

Year 3 and 4 Special Study Units:

- Diversity of endocrinology

Plenary lectures (years 1-2):

- Obesity and its complications
- Obesity and its treatment
- Early life origins of adult disease
- Diabetes and its complications
- Obesity and its treatment (dental school)
- Endocrinology (dental school)

Year 4 CPC/SSL:

- Thyroid and adrenal disease
- Matching clinical and laboratory diagnosis – data interpretation.
- Chronic disease management

Year 4 Clinical Skills

- Diabetes clinical skills

Year 3-5:

- Non-specific symptoms pathway
- Hypertension pathway
- Year 5 attachments

## **PUBLICATIONS:**

### **(i) Peer reviewed papers:**

**Pinkney JH**, Bingley PJ, Sawtell P, Dunger D, & Gale EAM. Presentation and progress of childhood diabetes mellitus: A prospective population based study. *Diabetologia* 1994;37:70-74.

**Pinkney JH**, Mohamed-Ali V, Denver AE, Sampson MJ, & Yudkin JS. Insulin resistance, insulin, proinsulin and ambulatory blood pressure in non-insulin dependent diabetes mellitus. *Hypertension* 1994;24:362-367.

**Pinkney JH**, Foyle W-J, Denver AE, McKinlay S, & Yudkin JS. The relationship of urinary albumin excretion rate to sodium-lithium countertransport in non-insulin dependent diabetes mellitus. *Diabetologia* 1995;38:356-362.

**Pinkney JH**, Denver AE, Mohamed-Ali V, & Yudkin JS. Insulin resistance in NIDDM

is related to microalbuminuria independently of ambulatory blood pressure. *Journal of Diabetes and its Complications* 1995;9:230-233.

**Pinkney JH**, Denver AE, Foyle WJ, Foster C, & Yudkin JS. Insulin resistance and not hyperinsulinaemia determines erythrocyte  $\text{Na}^+/\text{Li}^+$  countertransport in NIDDM. *Journal of Human Hypertension* 1995;9:685-686.

Sampson MJ, Denver AE, Foyle W, **Pinkney JH**, & Yudkin JS. Left ventricular hypertrophy and membrane cation transport in normotensive subjects with and without type-2 diabetes. *Diabetologia* 1995;38:454-460.

Foyle W-J, Fernandez M, Carstensen E, Denver AE, Sampson MJ, **Pinkney JH**, & Yudkin JS. Cellular sodium membrane transport and cardiovascular risk factors in non-insulin dependent diabetes mellitus. *Metabolism* 1996;8:961-965.

**Pinkney JH**, Stehouwer CD, Coppack SW, & Yudkin JS. Endothelial dysfunction: Cause of the Insulin Resistance Syndrome. *Diabetes* 1997; 46 (suppl 2) S9-13.

Mohamed-Ali V, **Pinkney JH**, Panahloo AA, Goodrick S, & Yudkin JS. Plasma leptin in NIDDM: Close relationships with obesity, insulin and insulin resistance. *Diabetic Medicine* 1997; 14: 376-481.

**Pinkney JH**, Denver AE, & Yudkin JS. Ambulatory blood pressure monitoring in diabetes: An evaluation of its clinical role. *Cardiovascular Risk Factors* 1998; 8:1-7.

Mohamed-Ali V, **Pinkney JH**, Panahloo AA, Cwyfan-Hughes S, Holly JMP, & Yudkin JS. Insulin-like growth factor binding protein-1 in NIDDM: relationship with the insulin resistance syndrome. *Clinical Endocrinology* 1999;50:221-228.

**Pinkney JH**, Goodrick S, Katz J, Johnson AB, Lightman SL, Coppack SW, & Mohamed-Ali V. Leptin and the pituitary-thyroid axis: A comparative study in lean, obese, hypothyroid and hyperthyroid subjects. *Clinical Endocrinology* 1998; 49:583-589.

**Pinkney JH**, Coppack SW, & Mohamed-Ali V. Effect of isoprenaline on plasma leptin and lipolysis in humans. *Clinical Endocrinology* 1998 ;48: 407-411.

Coppack SW, **Pinkney JH**, & Mohamed-Ali V. Leptin production in human adipose tissue. *Proceedings of the Nutrition Society* 1998 ;57:461-470.

Jackson SN, **Pinkney JH**, Bargiotta A, Veal CD, Howlett TA, McNally PG, Corrall R, Johnson A, & Trembath RC. A defect in the regional deposition of adipose tissue (partial lipodystrophy) is encoded by a gene at chromosome 1q. *American Journal of Human Genetics* 1998;63:534-540.

**Pinkney JH**, Downs L, Hopton M, Mackness M, & Bolton CH. Endothelial dysfunction in type-1 diabetes: relationship with LDL oxidation and the effects of vitamin-E. *Diabetic Medicine* 1999;16:993-999.

**Pinkney JH**, Vernon P, Carstensen E, Gillies S, Phillips DIW & Yudkin JS. Relationship of sodium membrane transport with birthweight. *Clinical Physiology* 2001;21:640-647.

**Pinkney JH**, Goodrick SW, Katz J, Johnson AB, Lightman SL, Medbak S, Coppack SW & Mohamed-Ali V. Thyroid and sympathetic influences on leptin production in hypothyroidism and hyperthyroidism. *International Journal of Obesity* 2000: 24 (suppl 1):S1-S2.

Mohamed-Ali V, Bulmer K, Goodrick S, Coppack SW & **Pinkney JH**. b-adrenergic regulation of plasma cytokines in humans. *International Journal of Obesity* 2000: 24 (suppl 2):S154-155.

**Pinkney JH**, Boss O, Bray GA, Lin L, Kilroy G, Coppack SW and Mohamed-Ali V. Physiological correlates of uncoupling protein-2 gene expression in human adipose tissue. *Journal of Clinical Endocrinology and Metabolism* 2000;85:2312-2317.

Bolton CH, Downs L, Victory J, Dwight J, Tomson CMV, **Pinkney JH**. Endothelial dysfunction in chronic renal failure: Roles of proinflammatory cytokines and LDL oxidation. *Nephrology Dialysis & Transplantation* 2001;16:1189-1197.

Mohamed-Ali V, Flower L, Sethi J, Hotamisligil G, Gray R, Humphries SE, York DA, **Pinkney JH**. b-Adrenergic regulation of interleukin-6 in adipose tissue : in vitro and in vivo studies. *Journal of Clinical Endocrinology and Metabolism* 2001;86:5864-5869.

Mohamed-Ali V, Armstrong L, Bulmer K, Bolton CH, & **Pinkney JH**. Plasma cytokines in type-1 diabetes: Relationships with circulating adhesion molecules. *Journal of Internal Medicine* 2001; 250(5):415-21.

**Pinkney JH**, Sjostrom CD, Gale EAM. Should surgeons treat diabetes in severely obese people? *Lancet* 2001: 357;1357-1359.

**Pinkney JH** and Williams G. Ghrelin gets hungry. *Lancet* 2002;359: 1360-1361.

**Pinkney JH**. Prevention and cure of type 2 diabetes. *British Medical Journal* 2002; 325:232-234.

**Pinkney JH**, Wilding JP, Williams G, MacFarlane I. Hypothalamic obesity in humans: What do we know and what can be done? *Obesity Reviews* 2002; 3:27-34.

Flower L, Gray R, & **Pinkney JH**, Mohamed-Ali V. Stimulation of interleukin-6 secretion by interleukin-1b in primary human adipocytes. *Cytokine* 2002;1 (6): 399-410.

MacFarlane IA, Gill GV, Finnegan D, & **Pinkney J**. Diabetes in a high secure hospital. *Postgraduate Medical Journal* 2004;80:35-37.

Daousi C, Dunn A, Foy P, Macfarlane IA, & **Pinkney JH**. Endocrine and anatomical



predictors of weight gain in adults with craniopharyngioma. *American Journal of Medicine* 2005;118:45-50.

Daousi C, Macfarlane IA, English P, Wilding JPH, Patterson M, Dovey T, Halford J, Ghatei M, & **Pinkney JH**. Is there a role for ghrelin and peptide-YY (3-36) in the pathogenesis of obesity in adults with acquired structural hypothalamic damage? *Journal of Clinical Endocrinology and Metabolism* 2005;90: 5025-5030.

Wong S, English P, Huda B, Wilding JPH, Bargiotta A, Johnson AB, Corrall RJ, & **Pinkney JH**. Plasma adipokine secretion in familial partial lipodystrophy caused by a mutation in Lamin A/C. *Diabetologia* 2005;48:2641-2649.

Daousi C, Casson I, Gill GG, Macfarlane IA Wilding J, & **Pinkney JH**. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. *Postgraduate Medical Journal* 2006;82:280-284.

Tomlinson JA, Hattersley AT, **Pinkney JH**. Screening for diabetes and hyperglycaemia in rural North Cornwall. *Diabetes and Primary Care* 2006; 8:106-113.

Huda M.S.B., Durham B.H., Wong S.P., Dovey T.M., McCulloch, P. Kerrigan, D., **Pinkney J.H.**, Fraser W.D. and Wilding J.P.H. Lack of an Acute Effect of Ghrelin on Markers of Bone Turnover in Healthy Controls and Post-Gastrectomy Subjects. *Bone*. 2007;41:406-13.

Huda M.S.B., Durham B.H., Wong S.P., Deepak D., Kerrigan D., McCulloch P., Ranganath L., **Pinkney J.** and Wilding J.P.H. Plasma Obestatin levels are Lower in Obese and Post-Gastrectomy subjects, but Do Not Change in Response to a Meal. *Int J Obes (Lond)*. 2008;32:129-35.

Harrold JA, Dovey T, Cai XJ, Halford JC, **Pinkney JH**. Autoradiographic analysis of ghrelin receptors in rat hypothalamus. *Brain Research* 2008; 1196:59-64.

Deepak D, Daousi C, Boyland E, **Pinkney JH**, Wilding JPH, and Macfarlane IA. Growth hormone and changes in energy balance in growth hormone deficient adults. *Eur J Clin Invest* 2008;38:622-627.

Daousi C, Cleator J, Halford J, Wilding JPH, **Pinkney JH**, Ranganath L. Effects Of Peripheral Administration Of Synthetic Human Glucose-Dependent Insulinotropic Peptide (GIP) On Energy Expenditure And Subjective Appetite Sensations In Healthy Normal Weight Subjects And Obese Patients With Type 2 Diabetes. *Clinical Endocrinology* 2009 (in press). Oct 20.Epub ahead of print.

Huda MSB, Dovey T, Wong SPY, English PJ, Halford J, McCulloch P., Cleator, J, Martin B, Cashen J, Hayden K, Wilding JPH and **Pinkney JH**. Ghrelin restores 'lean-type' hunger and energy expenditure profiles in morbidly obese subjects but has no effect on post-gastrectomy subjects. *Int J Obesity* 2009;33:317-25.

White HD, Blair J, **Pinkney J**, Cuthbertson DJ, Day R, Weber A, MacFarlane IA. Improvement in the care of multiple endocrine neoplasia type 1 through a regional multidisciplinary clinic. *QJM*. 2010 May;103(5):337-45.

Kos K, Wong S, Tan B, Gummesson A, Jernas M, Franck N, Kerrigan D, Nystrom FH, Carlsson LMS, Randevara H, **Pinkney JH**, Wilding JPH. Regulation of the fibrosis and angiogenesis promoter SPARC/osteonectin in human adipose tissue by weight change, leptin, insulin and glucose. *Diabetes* 2009;58(8):1780-8.

Davies M, Lavallo-González F, Storms F, Gomis R; **AT.LANTUS Study Group**. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. *Diabetes Obes Metab*. 2008;10:387-99.

**Pinkney JH**. Bariatric surgery for diabetes: Gastric banding is simple and safe. *Br J Diabetes and Vasc Dis* 2010; 10: 3139-142

Mracek T, Ding Q, Tzanavari T, Kos K, **Pinkney J**, Wilding J, Trayhurn P, Bing C. The adipokine zinc-alpha2-glycoprotein (ZAG) is downregulated with fat mass expansion in obesity. *Clin Endocrinol (Oxf)*. 2010 Mar;72(3):334-41

Deepak D, Daousi C, Javadpour M, Clark D, Perry Y, **Pinkney J**, Macfarlane IA. The influence of growth hormone replacement on peripheral inflammatory and cardiovascular risk markers in adults with severe growth hormone deficiency. *Growth Horm IGF Res*. 2010 Jun;20(3):220-5.

Kos K, Wong SP, Huda MS, Cakir M, Jernas M, Carlsson L, Kerrigan D, Wilding JP, **Pinkney JH**. In humans the adiponectin receptor R2 is expressed predominantly in adipose tissue and linked to the adipose tissue expression of MMIF-1. *Diabetes Obes Metab*. 2010 Apr;12(4):360-3.

Kos K, Wong S, Bee T, Kerrigan D, Harpal S, Randevara, **Pinkney JH**, Wilding JPH. RBP4 adipose tissue expression in humans is gender specific and influenced by leptin in women. *Clin Endocrinol (Oxf)*. 2011 Feb;74(2):197-205.

Huda MS, Mani H, Dovey T, Halford JC, Boyland E, Daousi C, Wilding JP, **Pinkney J**. Ghrelin Inhibits Autonomic Function in Healthy Controls, but has No Effect on Obese and Vagotomized Subjects. *Clin Endocrinol (Oxf)*. 2010 Clin Endocrinol (Oxf). 2010 Nov;73(5):678-85.

Kos K, Wong S, Tan BK, Kerrigan D, Randevara HS, **Pinkney JH**, Wilding JP. Human RBP4 adipose tissue expression is gender specific and influenced by leptin. *Clin Endocrinol (Oxf)*. 2011 Feb;74(2):197-205.

Huda MS, Dovey TM, Wong SP, English PJ, Halford JC, McCulloch P, Cleator J, Martin B, Cashen J, Hayden K, Ghatei MA, Bloom SR, Wilding JP, **Pinkney JH**. Ghrelin does not orchestrate the metabolic changes seen in fasting but has significant effects on lipid mobilisation and substrate utilisation. *Eur J Endocrinol*. 2011 Jul;165(1):45-55.

Daousi C, **Pinkney JH**, Cleator J, Wilding JP, Ranganath LR. Acute peripheral administration of synthetic human GLP-1 (7-36 amide) decreases circulating IL-6 in obese patients with type 2 diabetes mellitus: a potential role for GLP-1 in modulation of the diabetic pro-inflammatory state? *Regul Pept*. 2013 May 10;183:54-61

Plasma obestatin and autonomic function are altered in orexin-deficient narcolepsy, but ghrelin is unchanged. Huda MS, Mani H, Durham BH, Dovey TM, Halford JC, Aditya BS, **Pinkney JH**, Wilding JP, Hart IK. *Endocrine*. 2013 Jun;43(3):696-704

Ajala O, English P, **Pinkney J**. Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes. *Am J Clin Nutr*. 2013 Mar;97(3):505-16.

Cooper R, **Pinkney J**, Ayling RM. Appropriateness of prescribing thyroxine in primary care. *Ann Clin Biochem*. 2015 Jan 9. (ePub ahead of print).

Clarke-Harris R, Wilkin TJ, Hosking J, **Pinkney J**, Jeffery AN, Metcalf BS, Godfrey KM, Voss LD, Lillycrop KA, Burdge GC. Diabetes. PGC1 $\alpha$  promoter methylation in blood at 5-7 years predicts adiposity from 9 to 14 years (EarlyBird 50). *Diabetes* 2014 Jul;63(7):2528-37.

]

**Pinkney J**, Streeter A, Hosking J, Mohammad M, Jeffery A, Wilkin T. Adiposity, chronic inflammation, and the prepubertal decline of sex hormone binding globulin in children: evidence for associations with the timing of puberty (Earlybird 58). *J Clin Endocrinol Metab*. 2014 Sep;99 (9):3224-32

Aljwaid H, White D, Collard K, Moody AJ, **Pinkney JH**. Non-transferrin-bound iron is associated with biomarkers of oxidative stress, inflammation and endothelial dysfunction in type 2 diabetes. *Journal of Diabetes and its Complications* 2015 Sep-Oct;29(7):943-9.

Swancutt S, Joel-Edgar S, Allen M, Thomas D, Brant H, Bengner J, Byng R, **Pinkney J**. Not all waits are equal: An investigation of emergency care patient pathways. *BMC Health Service Research* (submitted 2015).

Tomlinson J, Mari A, Tura A, Bond K, Stenhosue E, Vincent R, **Pinkney J**. Origin of Diabetes in Women with Polycystic Ovary Syndrome. (Submitted to *New England Journal of Medicine*, 2015).

ii) **Review articles:**

**Pinkney J.** The role of ghrelin in metabolic regulation. *Curr Opin Clin Nutr Metab Care.* 2014 Nov;17(6):497-502.

**Pinkney JH, Johnson AB, Gale EA.** The big fat bariatric bandwagon. *Diabetologia.* 2010 Sep;53(9):1815-22.

**Pinkney JH.** The surgical panacea for diabetes: time for diabetologists to discriminate facts from fiction and flights of fantasy. *Practical Diabetes International* 2011 ; 28(2): 76-80.

**Pinkney J, Fox T, Ranganath L.** Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide. *Ther Clin Risk Manag.* 2010 Sep 7;6:401-11

Tomlinson J, Millward A, Stenhouse E, **Pinkney J.** Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced? *Diabet Med.* 2010 May;27(5):498-515.

**Pinkney JH** and Kerrigan DK. When to consider antiobesity drugs and bariatric surgery? *Diabetes and Primary Care* 2007;9:82-92.

Huda M, Wilding JPH and **Pinkney JH.** Gut peptides and the regulation of appetite. *Obesity Reviews* 2006;7:163-82.

Harrold JA, **Pinkney JH,** Williams G. Control of obesity through the regulation of appetite. *Drug Discovery Today* 2005 (in press).

Wong S and **Pinkney J.** Role of cytokines in regulating feeding behaviour. *Curr Drug Targets.* 2004; 5:251-63.

**Pinkney JH** and Kerrigan DK. When should bariatric surgery be used in the treatment of type 2 diabetes? *British Journal of Diabetes and Vascular Medicine* 2004;4:232-237.

**Pinkney JH** and Kerrigan DK. Current status of bariatric surgery in the treatment of type 2 diabetes. *Obesity Reviews* 2004;5:69-78.

**Pinkney JH.** Treating diabetes and CHD: what should we do about obesity? *Cardiabetes* 2002;1:9-16.

Mohamed-Ali V, **Pinkney JH,** & Coppack SW. Adipose tissue as an endocrine and paracrine organ. *International Journal of Obesity* 1998;22;1145-1158.

Mohamed-Ali V & **Pinkney JH.** Therapeutic potential of Insulin-like Growth Factor-1 in patients with Diabetes Mellitus. *Treatments in Endocrinology* 2002 ; 1(6): 399-410.

**Pinkney JH.** Implications of obesity for diabetes and coronary heart disease in clinical practice. *British Journal of Diabetes and Vascular Disease* 2001;1:103-106.

**Pinkney JH & Yudkin JS.** Antihypertensive drugs : Issues beyond blood pressure control. *Progress in Cardiovascular Diseases* 1994;XXXVI:397-415.

**Pinkney JH, Nagi D, & Yudkin JS.** From Syndrome X to the thrifty phenotype: A reappraisal of the insulin resistance theory of atherogenesis. *Vascular Medicine Review* 1993;4:19-47.

**(iii) Other publications:**

O’Kane M, **Pinkney J**, Arsheim E et al. BOMSS Guidelines on peri-operative and postoperative biochemical monitoring and micronutrient replacement for patients undergoing bariatric surgery <http://www.bomss.org.uk/wp-content/uploads/2014/09/BOMSS-guidelines-Final-version1Oct14.pdf>

**Pinkney J.** Surgery for diabetes: Can theory translate into clinical practice? *Diabetes* 2015; 4(1):12-13.

**Pinkney JH.** How can primary care rise to the challenge of obesity? *Diabetes and Primary Care* 2006; 8 (supplement): 3-8.

Wallymahmed ME, **Pinkney JH**, Saunders S, Macfarlane IA. Vascular risk factors with type 1 diabetes. *Practical Diabetes* 2005;3:81-85.

**Pinkney JH** and Kerrigan K. Expanding role of bariatric surgery in the private sector. *Private Hospital Healthcare Europe* 2005; T23-T25.

**Pinkney JH.** Feeding, growth hormone secretion and gastric function: Enter ghrelin! *Current Medical Literature Diabetes* 2001;18:85-89.

**Pinkney JH.** Ghrelin; a new hormone in body weight regulation. *Diabetes Digest* 2001;1 (1):26-27.

**Pinkney JH.** Diabetes and left ventricular hypertrophy revisited. *Diabetes Digest* 2001;1 (2):92-101.

**Pinkney JH.** Central obesity: also a silent killer in type 1 diabetes. *Diabetes Digest* 2002 (3):165-166.

**Pinkney JH.** Controlling the epidemic of type 2 diabetes in the United Kingdom has to begin in childhood. *Diabetes Digest* 2002 (4):238-240.

**Pinkney JH.** Results from four decades of antiobesity drug trials – what hope for weight loss in diabetes? *Diabetes Digest* 2002; (5): 312-313.

**Pinkney JH.** Obesity and heart disease risk in women with diabetes. *Diabetes Digest* 2002; (6): 372-373.

**Pinkney JH.** Waist circumference action thresholds revisited. *Diabetes Digest* 2003; 2(1): 34-43.

**Pinkney JH.** Sleep-disordered breathing and diabetes. *Diabetes Digest* 2003; 2 (2); 105-107.

**Pinkney JH.** Who is for a very low calorie diet? *Diabetes Digest* 2003; 2 (3): 192-194.

**Pinkney JH.** Whom should we target for diabetes prevention? *Diabetes Digest* 2003; 2 (4); 258-259.

**Pinkney JH.** Slim Fast with Reductil and Slim Fast? *Diabetes Digest* 2004; 3 (1): 27-29.

**Pinkney JH.** Bariatric surgery in the treatment of type 2 diabetes. *Diabetes Digest* 2004;3 (2) (in press).

**Pinkney JH.** Comparison of the effects of low-carbohydrate versus low fat diets. *Diabetes Digest* 2004, 3 (3) 160-161.

**Pinkney JH.** How does gastric bypass surgery cure type 2 diabetes? *Diabetes Digest* 2004, 3 (4) 236-237.

**Pinkney JH.** Rimonabant: A golden bullet for “diabesity”? *Diabetes Digest* 2005, 4 (3) 166-167.

**Pinkney JH.** The changing face of childhood diabetes: Hyperosmolar non-ketotic hyperglycaemia. *Diabetes Digest* 2005;4 (in press).

**Pinkney JH.** Regular walking or light jogging for 60 minutes effectively reduces body fat in people with type 2 diabetes. *Diabetes Digest* 2006; 5: 31-32.

**Pinkney JH.** Obesity in your diabetic clinic – A prominent cardiovascular risk factor. *Diabetes Digest* 2006;5:98-100.

**Pinkney JH.** Diabetes in high risk groups: Opportunities for screening and prevention. *Diabetes Digest* 2006;5:241-244.

**Pinkney JH.** Rimonabant for type 2 diabetes? *Diabetes Digest* 2007;6:28-30.

**Pinkney JH.** Intermittant claudication, diabetes and obesity. *Diabetes Digest* 2007.

**Pinkney JH.** Group-based diabetes prevention is likely to be cost-effective. *Diabetes Digest* 2008; 7(1);30-32.

**Pinkney JH.** Can behavioural intervention help at-risk people increase their physical activity? *Diabetes Digest* 2008;7(1):51.

**Pinkney JH.** Why not now bariatric surgery for type 2 diabetes? *Diabetes Digest* 2008; 7: 97-98.

**Pinkney JH.** Is insulin-induced weight gain an excuse for overeating? *Diabetes Digest* 2008; 7: 163-164.

**Pinkney JH.** Preventing type 2 diabetes: Time for tapas? *Diabetes Digest* 2008; 8: pp.

**Pinkney JH.** Charcot arthropathy: A mechanical complication of obesity. *Diabetes Digest* 2009; 8: 34-35.

**Pinkney JH.** A low carbohydrate ketogenic diet is superior to a low glycaemic index diet for people with type 2 diabetes. *Diabetes Digest* 2009;8(2):86-87.

**Pinkney JH.** Laparoscopic adjustable gastric banding proves a cost-effective treatment for type 2 diabetes. *Diabetes Digest* 2009;8(3):146-147.

**Pinkney JH.** GLP-1 mimetic therapy for diabetes: Liraglutide flexes its muscles *Diabetes Digest* 2009; 8 :204-205.

**Pinkney JH.** How much of the increase in type 2 diabetes is explained by obesity? *Diabetes Digest* 2010.

**Pinkney JH.** Screening for diabetes in asymptomatic high risk subjects. HbA1c fails the test. *Diabetes Digest* 2011.

**Pinkney JH.** Weight matters for pituitary patients. *Pituitary Life* 2008 (summer edition)

Wong S, and **Pinkney JH.** Impact of visceral obesity on diabetes and complications. *Current Medical Literature Diabetes* 2006.

**Pinkney JH.** Obesity and Pituitary Disease. *Pituitary News* 2000;17 (autumn): 4-5.

**Pinkney JH.** Clinical Overview of Diabetes. *Optometry Today* Shared Care Series, 1997; Diabetes Modules 1-12: 1-7. Association of Optometrists. Mayhew McCrimmon, UK.

**Pinkney JH.** Diabetes Mellitus: A Clinical Overview. *Optometry Today* 1996;Jan 15; 26-32. (Review and multiple choice questions).

**Pinkney JH,** Catnach S, Woods AW & Fairclough PDF. Coronary thrombolysis: Still

too little too late. *Health Trends* 1994;25:132-134.

**Pinkney JH**, Clarke G, & Fairclough P.D. Gastrointestinal Haemorrhage in Wegener's Granulomatosis. *Gastrointestinal Endoscopy* 1991;37:411-412.

Heard S, **Pinkney JH**, & Tunstall-Pedoe DS. Pneumococcal endocarditis and disseminated infection. *Journal of Clinical Pathology* 1992;45:1034-1035.

Browett PJ, Pattinson J, **Pinkney JH**, Hoffbrand AV, & Norton J. Gene probe analysis demonstrates independent clonal evolution of co-existent chronic myeloid and chronic lymphocytic leukaemia. *European Journal of Haematology* 1988;40:181-4.

**(iv) Book chapters**

**Pinkney JH**, Tomlinson J, Stenhouse E. Overview of type 2 diabetes. Chapter 2. *In Nutritional and therapeutic aspects of diabetes*. pp15-26. Editors Bagchi and Nair. Elsevier 2012.

Fox T and **Pinkney JH**. Obesity and weight management. Chapter in *Essentials of Medicine in Psychiatry*. Eds Cormac I and Gray D. Gaskell Press, 2009.

**Pinkney JH**, Daousi D, MacFarlane IA. Recent advances in the understanding and treatment of human hypothalamic obesity. Chapter in *Focus on Obesity Research*. Ed Ling, P. Nova Science Publishers. 2005. pp41-66.

**Pinkney JH & Kopelman P**. Endocrine determinants of obesity. Chapter in *Handbook of Obesity*. Eds Bray GA and Bouchard C. 2<sup>nd</sup> edition, 2003. Marcel Dekker, New York.

**Pinkney JH**. Clinical research methods in diabetes. Chapter 35 in a *Textbook of Diabetes*. Eds Williams G and Pickup J. 3<sup>rd</sup> edition, 2002. Blackwell, Abingdon, UK.

**Pinkney JH** and Wilding JPH. The poorly controlled type 2 diabetic patient. Chapter in *Brittle and Unstable Diabetes*. Ed Gill GV. Martin Dunitz, 2003.

Kerrigan DK, Evans J, & **Pinkney JH**. The role of bariatric surgery in the management of type 2 diabetes. Chapter in "Obesity and Diabetes", 2004. Eds Barnett AH & Kumar S. John Wiley & Sons. pp 215-231. ISBN 0-470-84898-7.

**Pinkney JH**. Obesity and Disease: Role of Hormones. Chapter in *Clinical Obesity* 3<sup>rd</sup> edition. Eds Kopelman P, Dietz W, & Caterson I. Blackwell, Abingdon, UK. (In press 2004).

Kerrigan DK & **Pinkney JH**. The role of metabolic surgery in the management of type 2 diabetes. Chapter in "Obesity and Diabetes", 2<sup>nd</sup> edition, 2009. Eds Barnett AH & Kumar S. John Wiley & Sons

**Pinkney JH**. Prevention and treatment of Obesity. Chapter in "Essentials of physical



health in psychiatry”: Ed Cormac I. Gaskell & Co. (In preparation 2009).

**(v) Letters:**

Jenkinson ML, **Pinkney JH**, & Tunstall-Pedoe DS. Computerised updating of clinical summaries. *British Medical Journal* 1989;298:258-9.

Catnach S, **Pinkney JH**, Woods A, & Fairclough PD. Fast-track admission policy for coronary thrombolysis. *British Medical Journal* 1992;302:204.

**Pinkney JH**, Mohamed-Ali V, Denver AE, Foster C, Sampson MJ, & Yudkin JS. Insulin Resistance, Insulin, Proinsulin and Ambulatory Blood Pressure in Type II Diabetes. *Hypertension* 1995.

**Pinkney JH**. *Continuing Medical Education in Endocrinology and Diabetes* 1999, Issue 2. (Comment).

**Pinkney JH**. BSE in the food chain. *Independent* 2000; Oct 30:2. (Letter to the Editor).

Dalal H, Short P, Michel N, **Pinkney JH**. Treating Primary Hyperparathyroidism with Pills. *British Medical Journal* 2009. 10<sup>th</sup> December. [http://www.bmj.com/cgi/eletters/339/nov20\\_1/b4613#227112](http://www.bmj.com/cgi/eletters/339/nov20_1/b4613#227112)

**Pinkney JH**. Obesity surgery. Big questions remain unanswered. *BMJ*. 2010 Sep 28;341:c5304. doi: 10.1136/bmj.c5304.

**(v) Posters and Oral Presentations:**

British Diabetic Association, Liverpool University, April 1993:

**Pinkney JH**, Foyle WJ, Denver AE, Sampson MJ, Yudkin JS. Ambulatory blood pressure, red cell sodium lithium countertransport, and platelet sodium hydrogen exchange in normotensive and hypertensive subjects with non-insulin dependent diabetes mellitus.

Sampson MJ, Denver AE, Foyle WJ, **Pinkney JH**, Yudkin JS. An association between left ventricular hypertrophy and elevated erythrocyte sodium-lithium countertransport rate in normotensive NIDDM subjects.

Foyle WJ, Denver AE, Sampson MJ, **Pinkney JH** Yudkin JS. The influences on membrane sodium transport in normotensive non-insulin dependent diabetic subjects.

British Diabetic Association, Southampton University, September 1993.

**Pinkney JH** Foyle WJ, Mohamed-Ali V, Denver AE, Yudkin JS. Blood pressure in non-insulin dependent diabetes mellitus (NIDDM): Relationships with insulin resistance, and sodium-lithium countertransport.

European Association for the Study of Diabetes, Istanbul, September 1993.

**Pinkney JH**, Mohamed-Ali V, Denver AE, Sampson MJ, Yudkin JS. In type-2 diabetes, blood pressure correlates with insulin resistance and not with levels of insulin or its precursors. **(Oral presentation)**.

Sampson MJ, Denver AE, Foyle W-J, **Pinkney J**, Yudkin JS. Sodium-lithium transport and left ventricular hypertrophy in normotensive type-2 diabetics and non-diabetics.

Foyle W-J, Denver AE, Sampson MJ, **Pinkney JH**, Yudkin JS. Sodium-lithium countertransport, sodium-hydrogen ion exchange and cardiovascular risk factors in type-2 diabetes.

University College London Postgraduate Student Poster Exhibition, July 1993.

**Pinkney JH**. Studies on blood pressure and insulin sensitivity in subjects with type-2 diabetes.

International Diabetes Federation, Kobe, Japan. November 1994.

**Pinkney JH**, Foyle W-J, Denver AE, Sampson MJ, Yudkin JS. Relationship between urinary albumin excretion rate and sodium-lithium countertransport. Insulin resistance in NIDDM is associated with microalbuminuria independently of blood pressure. **(Oral presentation)**.

European Association for the Study of Diabetes, Dusseldorf, September 1994.

**Pinkney JH**, Mohamed-Ali V, Panahloo AP, Yudkin JS. Relationships between concentrations of insulin, insulin precursors and hypertension in non-insulin dependent diabetes.

British Diabetic Association, Lancaster University. September 1994.

**Pinkney JH**, Foyle W-J, Denver AE, Foster C, Yudkin JS. Microalbuminuria in NIDDM is associated with hypertension in the absence of increases in sodium-lithium countertransport. **(Oral presentation)**.

Foyle W-J, Fernandez M, Carstensen E, **Pinkney JH**, Sampson MJ, Yudkin JS. Relationship between platelet sodium-hydrogen exchange and LV mass in normotensive diabetic and non-diabetic subjects.

London Hypertension Society 6th Annual Symposium. "New themes in Hypertension". London, March 1995.

**Pinkney JH**, Denver AE, Foyle WJ, Foster C, Yudkin JS. Insulin resistance and hyperinsulinaemia is associated with erythrocyte sodium-lithium countertransport in

NIDDM.

British Diabetic Association, Warwick University, March 1995.

**Pinkney JH**, Denver AE, Mohamed-Ali V, Owens D, Yudkin JS. Microalbuminuria in NIDDM: Evidence for an association between insulin resistance and endothelial dysfunction.

Anglo Danish Dutch Diabetes Group, Amsterdam, June 1995.

**Pinkney JH**. Is endothelial damage a precursor of the Insulin Resistance Syndrome?

British Diabetic Association, Harrogate, October 1995.

**Pinkney JH**, Mohamed-Ali V, Cwyfan-Hughes S, Holly JMP, Yudkin JS. Relationship of IGFBP-1 to dyslipidaemia in non-insulin dependent diabetic subjects.

European Association for the Study of Diabetes, Stockholm, September 1995.

**Pinkney JH**, Mohamed-Ali V, Foyle WJ, Denver AE, Yudkin JS. Insulin resistance and not hyperinsulinaemia determines erythrocyte sodium-lithium countertransport in NIDDM.

Medical Research Society, London, November 1995.

**Pinkney JH**, Vernon P, Yudkin JS. Nutritional and endocrine factors determine subsequent cell growth in neonatal rat fibroblasts: An in-vitro model of cell programming.

British Endocrine Society, University College Dublin, March 1996.

**Pinkney JH**, Mohamed-Ali V, Panahloo A, Holly JMP, Cwyfan-Hughes S, Yudkin JS. Insulin-like growth factor binding protein-1 concentrations in NIDDM: An independent relationship with the Insulin Resistance Syndrome?

British Diabetic Association, Exeter University, September 1996.

**Pinkney JH**, Mohamed-Ali V, Panahloo, A, Denver AE, Coppack SW, Yudkin JS. Plasma leptin in NIDDM: Close relationships with insulin, insulin resistance and obesity. **(Oral presentation)**.

**Pinkney JH**, Denver AE, Sampson MJ, Foster C, Yudkin JS. Ambulatory blood pressure monitoring demonstrates multiple defects in blood pressure variation in both hypertensive and normotensive non-insulin dependent diabetic subjects.

British Diabetic Association, Harrogate, 1997.

**Pinkney JH**, Mohamed-Ali V, Armstrong L, Bolton C, Hartog M. Endothelial soluble adhesion molecules VCAM-1, ICAM-1 and E-selectin in IDDM and non-diabetic

subjects: Relationships with levels of TNF $\alpha$  and IL-6.

**Pinkney JH**, Hopton M, Downs L, Hartog M, Bolton CH. Relationship of flow-mediated vasodilatation to the susceptibility of LDL to undergo in-vitro oxidative modification, plasma levels of antioxidants and serum lipoproteina in IDDM.

British Endocrine Society, Harrogate, 1997.

**Pinkney JH**, Mohamed-Ali V, Johnson AB, Yudkin JS, Lightman SL. Adipose tissue cytokines in hyperthyroidism and hypothyroidism: A possible role for leptin in the pathogenesis of energy disequilibrium.

American Diabetes Association, Boston, 1997.

**Pinkney JH**, Hopton M, Armstrong L, Hartog M, Bolton C. Endothelial dysfunction in IDDM is related to dyslipidaemia and susceptibility of LDL to oxidation in-vitro. **(Poster and oral discussion).**

**Pinkney JH**, Mohamed-Ali V, Panahloo A, Cwyfan-Hughes S, Holly JMP, Yudkin JS. Insulin-like growth factor binding protein-1 in NIDDM: Relationship with syndrome X.

Panahloo AA, Mohamed-Ali V, **Pinkney JH**, Goodrick S, Coppack SW, Yudkin JS. Relationship between plasma leptin and insulin concentrations, but not insulin resistance, in mom-insulin dependent diabetes mellitus.

American Endocrine Society, Minneapolis, 1997.

**Pinkney JH**, Mohamed-Ali V, Johnson AB, Yudkin JS, Lightman SL. Relationships of leptin, TNF $\alpha$  and IL-6, to free T3 in hyper and hypothyroidism.

British Diabetic Association, Bournemouth 1997.

**Pinkney JH**, Mohamed-Ali V, Kemp H, Coppack SW. Leptin and the pituitary thyroid axis in lean and obese non-diabetic subjects.

Society for Endocrinology, London 1997.

**Pinkney JH**, Coppack SW, Mohamed-Ali V. Effect of isoprenaline infusion on plasma leptin concentrations in-vivo.

**Pinkney JH**, Astley JP, Harrison R, Vyas S, Johnson AB. Thyroid storm masquerading as hyperemesis gravidarum.

British Diabetic Association, Edinburgh 1998.

Trembath R, Jackson S, **Pinkney JH**, Bargiotta A, Johnson AB, Corral RJ. Linkage of partial lipodystrophy (Dunnigan-Kobberling) syndrome on Chromosome 1q.

**Pinkney JH**, Hopton M, Hartog M, Bolton CH. A randomised controlled trial of the

effect of vitamin E on endothelial function in insulin-dependent diabetes mellitus.

British Endocrine Society, Edinburgh, 1998.

Mohamed-Ali V, Bulmer K, Coppack SW, **Pinkney JH**. b-adrenergic regulation of proinflammatory cytokines in humans in-vivo.

Morgan A, Holly JMP, **Pinkney JH**. Programming of growth by nutritional deprivation in adult and neonatal microvascular endothelial cells.

American Endocrine Society, New Orleans, 1998.

**Pinkney JH**, Mohamed-Ali V, Armstrong L, Bolton CH. Relationship of plasma cytokines with soluble adhesion molecules in insulin-dependent diabetes mellitus. (**Oral presentation**).

Bolton CH, Hopton, ML. Mohamed-Ali V, **Pinkney JH**. Relationship of plasma retinol to cardiovascular risk factors in insulin dependent diabetes mellitus.

**Pinkney JH**, Goodrick S, Coppack SW, Johnson AB, Lightman SL, Mohamed-Ali V. Pituitary-thyroid axis and plasma leptin in euthyroid and dysthyroid subjects.

Mohamed-Ali, Bulmer K, Coppack SW, **Pinkney JH**. Beta-adrenergic regulation of plasma cytokines in-vivo. (**Oral presentation**).

Endocrinology of Obesity, Venice, 1998.

**Pinkney JH**, Goodrick SW, Katz J, Johnson AB, Lightman SL, Medbak S, Coppack SW & Mohamed-Ali V. Thyroid and sympathetic influences on leptin production in hypothyroidism and hyperthyroidism.

Mohamed-Ali V, Bulmer K, Coppack SW & **Pinkney JH**. b-adrenergic regulation of plasma cytokines.

Federation of American Societies for Experimental Biology, Washington 1999.

**Pinkney JH**, Mohamed-Ali V, Lin L, York DA, Bray GA. Does interleukin-6 modulate the b<sub>3</sub>-adrenergic suppression of food intake?

British Diabetic Association, Glasgow 1999.

**Pinkney JH**, Boss O, Bray GA, Bulmer K, Coppack SW, Mohamed-Ali V. Uncoupling protein-2 gene expression is inversely related to adiposity in human subcutaneous adipose tissue. (**Oral presentation**).

Mohamed-Ali V, Flower,L, Swallow R, Sethi R, Hotamisligil G, York DA, **Pinkney JH**. In vivo and in vitro studies on the adrenergic regulation of interleukin-6.

Renal Association of Great Britain, Dublin 1999

Downs LG, Victory J, Bolton CH, Tomson CMV, **Pinkney JH**, Dwight J. Endothelial function, lipids and lipid oxidation in chronic renal failure.

Endocrine Society, San Diego, California, 1999.

**Pinkney JH**, Boss O, Bray GA, Bulmer K, Coppack SW, Mohamed-Ali V. Uncoupling protein-2 gene expression is inversely related to adiposity in human subcutaneous adipose tissue. **(Oral presentation)**.

Mohamed-Ali V, Clarke D, **Pinkney JH**, Uysal KT, Hotamisligil GS. Expression and secretion of Interleukin-6 during adipogenesis.

European Congress on Obesity, Milan, 1999.

**Pinkney JH**, Mohamed-Ali V, Lin L, Kilroy G, Bray GA, York DA. An investigation of the role of Interleukin-6 and prostaglandins in the suppression of food intake by b3-adrenergic agonists.

British Diabetic Association, Brighton, 2000.

Mohamed-Ali V, Browne E, Flower L, Gray R, **Pinkney JH**. Effect of Diabetes on the inhibition of Interleukin-6 production by Aspirin on peripheral blood cells **(oral presentation)**.

British Endocrine Society / Federation of European Endocrine Societies, Birmingham, 2000.

**Pinkney JH**, Downs LG, Victory J, Dwight JF, Tomson CMV, Bolton CH. Proinflammatory cytokines and vascular disease in chronic renal failure.

Endocrine Society, Toronto 2000.

**Pinkney JH**, Bolton CH, Downs LG, Victory J, Dwight JSF, Tomson CMV. Plasma cytokines in chronic renal failure are related to endothelial dysfunction and risk factors for ischaemic heart disease.

British Endocrine Society, Harrogate 2002.

Daousi C, MacFarlane IA, **Pinkney JH**. Endocrine characteristics associated with weight gain in humans with hypothalamic damage.

Diabetes UK, Glasgow 2003.

Daousi C, and **Pinkney JH**. Impact of obesity on diabetes mellitus and its complications.

Endocrine Society, Philadelphia, 2003.

Daousi C, and **Pinkney JH**. Endocrine and radiographic predictors of weight gain in patients with structural disease of the hypothalamus.

Diabetes UK, Birmingham 2004.

Carroll P and **Pinkney J**. Weight gain, antipsychotic drug medication and diabetes mellitus among detained psychiatric patients.

Wong S, English P, Huda M, Wilding JPH, Bargiotta A, Corrall R, Johnson AB and **Pinkney JH**. Evidence for the involvement of Adiponectin and Tumour Necrosis Factor- $\alpha$  in the pathophysiology of the metabolic syndrome in Lipotrophic Diabetes (Dunnigan Kobberling Syndrome).

Wong S, Pazmany L, Cakir M and **Pinkney JH**. Transcriptional regulation of adiponectin but not resistin gene expression by adrenergic agonists in differentiated human and murine adipocytes.

British Endocrine Societies, Brighton, 2004

**Pinkney JH**, Macfarlane IA, Ellard S, Cave-Bigley D. A clinic for Multiple Endocrine Neoplasia highlights needs for greater family awareness of type 1 MEN and for genetic testing of other family members.

Wong S, Huda B, Pazmany L, Hart I, **Pinkney JH**. Excessive daytime sleepiness associated with hypercytokinaemia in Crow-Fukase (POEMS) syndrome.

Endocrine Society, New Orleans, 2004

Daousi C, English P, Wilding JPH, Halford J, Dovey T, Patterson M, Ghatei M, Macfarlane IA, **Pinkney JH**. Plasma ghrelin and peptide YY in human hypothalamic obesity.

British Pharmacological Society 2004. Obesity: Novel targets and treatments. University of Buckingham.

Manipulation of luminal glucose availability increases ghrelin concentrations in plasma but not in stomach or duodenum. Cai XJ, Harrold JA, Berwaer M, Williams G and **Pinkney JH**.

Plasma ghrelin levels are increased in Streptozotocin-induced diabetes and insulin-induced hypoglycaemia Cai XJ, Berwaer M, Williams G and **Pinkney JH**.

*[<sup>125</sup>I-His<sup>9</sup>]-ghrelin autoradiography demonstrates ghrelin binding sites in the lateral hypothalamus. Harrold JA, Cai XJ, Dovey T, Halford J, and **Pinkney JH**.*

**Society for the Study of Ingestive Behaviour, Cincinnati, 2004**

Changes in food intake and microstructure of a meal in response to a physical

stressor. Dovey TM, Ball MF, Clark KG, Rodgers A, **Pinkney J**, Halford JCG.

North American Association for the Study of Obesity, Las Vegas, 2004

Does impaired satiety contribute to human hypothalamic obesity? Daousi C, English P, Dovey T, MacFarlane IA, Wilding JPH, Halford JCG, and **Pinkney JH**.

Endocrine Society, Boston, 2006.

Administration of Ghrelin restores 'Lean-type' Hunger Profiles in the Morbidly Obese. Huda MSB, Dovey T, Wong SP, English PJ, Halford J, Wilding JPH, and **Pinkney J**.

International Congress on Obesity, Sydney 2006.

Ghrelin increases respiratory quotient in obese subjects. Huda MSB, Dovey T, Wong SP, English PJ, Halford J, Wilding JPH, and **Pinkney JH**. (**Oral presentation**).

British Endocrine Society, Birmingham, 2006

The influence of growth hormone replacement (GHR) in adults with growth hormone deficiency (GHD) on body composition, basal metabolic rate, physical activity and ingestive behaviour. Deepak D, Wilding JPH, **Pinkney JH**, and MacFarlane IA.

International Diabetes Federation, Capetown, December 2006

Regional adiponectin gene expression and serum levels: Close relationships with the metabolic syndrome and inflammatory state in lean and obese subjects Wong SPY, Huda MHB, Manel R, Evans J, Kerrigan D, Wilding JPH, **Pinkney JH**.

JA., Screening for diabetes and hyperglycaemia in rural South West England. Tomlinson Hattersley AT, **Pinkney JH**.

Sleep, Minneapolis, 2007

Changes in circulating plasma ghrelin and obestatin in narcolepsy-cataplexy. Huda MH, Dovey T, Durham M, **Pinkney JH**, Wilding JH, Hart I.

Plasma obestatin levels are lower in morbidly obese and post-gastrectomy subjects, but do not change in response to a meal. Huda MSB, Durham BH, Wong SP, Kerrigan DK, McCulloch P, **Pinkney J**, Ranganath L, Wilding JPH.

Effects of synthetic human GLP-1 (1-36 amide) and GIP on energy expenditure and appetite in obese patients with type 2 diabetes mellitus and in lean healthy subjects. Ranganath L, Daousi C, Cleator J, **Pinkney JH**, Wilding JPH.



The effect of GLP-1 on B-cell sensitivity to GIP in type 2 diabetes. Ranganath L, Daousi C, Cleator J, **Pinkney J**, Wilding JPH.

Endocrine Society, San Francisco 2008

Huda B, Durham M, Kerrigan D, **Pinkney JH**, Wilding JPH. Endocrine Adaptations to Short Term Fasting are Preserved after Gastrectomy but Impaired in Morbid Obesity

Deepak D, Daousi C, Halford J, **Pinkney JH**, MacFarlane IA, Wilding JPH. The influence of growth hormone (GH) replacement (GHR) in adults with GH deficiency (GHD) on resting energy expenditure, voluntary physical activity and ingestive behavior.

Deepak DS, Daousi C, **Pinkney JH**, Clark D, Perry Y, Wilding JPH, Macfarlane IA. Effects of 6 months growth hormone replacement (GHR) on proinflammatory cytokines in adults with severe growth hormone deficiency

Daousi C, Cleator J, Wilding JPH, Ranganath L, **Pinkney JH**. Acute Administration Of Synthetic Human GLP-1 (7-36 Amide) In Obese Patients With Type 2 Diabetes Mellitus Decreases Circulating IL-6 Levels But Does Not Alter Plasma Leptin And Adiponectin

Daousi C, Huda MH, **Pinkney JH**, Ranganath L, Wilding JPH. Plasma Obestatin And Ghrelin Levels During Acute Administration Of Synthetic Human GLP-1(7-36 Amide) And GIP In Obese Patients With Type 2 Diabetes And Lean Healthy Volunteers.

European Association for the Study of Diabetes, Rome 2008

**Pinkney JH**, Wong SPY, Huda MH, Kerrigan D, Wilding JPH. Distribution and characteristics of adiponectin R1 and R2 receptor gene mRNA expression in human adipose tissue. **(Oral presentation)**

Deepak D, **Pinkney J**, Macfarlane IA, Wilding JPH. The influence of growth hormone (GH) replacement (GHR) in adults with GH deficiency (GHD) on resting energy expenditure, voluntary physical activity and ingestive behaviour

Daousi C, Cleator J, **Pinkney JH**, Ranganath L, wilding JPH. Plasma Obestatin And Ghrelin Levels During Acute Administration Of Synthetic Human GLP-1(7-36 Amide) And GIP In Obese Patients With Type 2 Diabetes And Lean Healthy Volunteers

Kos C, Wong S, **Pinkney JH**, Wilding JPH. Adipose tissue derived SPARC and obesity related inflammation in healthy adults.

European Congress on Obesity, 2008

Kos K, Wong S, Huda B, **Pinkney JH**, Wilding JPH. Gender differences of RBP4 expression and relation of plasma, VAT and SCAT expression in humans, relation to insulin resistance and inflammation

British Endocrine Society, 2008

Kos K, Wong S, Kerrigan D, **Pinkney JH**, Wilding JPH. Unlike subcutaneous expression of IL-6 and IL-18, omental expression of IL-6, IL-18 and MCP-1 are not related to systemic cytokine levels in human obesity

K Kos, S Wong, D Kerrigan, **JH Pinkney**, JPH Wilding. SPARC expression in human adipose tissue is correlated with insulin resistance and fat mass

Evans K, Coupe A, Mascas R, Pilianidis G, **Pinkney J**. An audit of thyrotoxicosis management in Cornwall.

Association of Clinical Biochemists, 2008

Anna Barton, Roy Fisher, Kate Evans, **Jonathan Pinkney**. Concise thyroid function testing guidelines for use in primary care in Cornwall.

International Congress on Endocrinology, Mexico 2008.

Kos K, Wong S, Kerrigan D, **Pinkney JH**, Wilding JPH. The fibrosis promoter SPARC and its relation to the collagen-like adipokine adiponectin in human obesity

*Kos* K, Wong S, Kerrigan D, Wilding JPH, **Pinkney JH**. Depot-specific expression of MMIF, MCP-1 and MIP-1alpha in human adipose tissue in relation to systemic inflammation

Diabetes UK, APC Glasgow 2009 (invited lecture).

**Pinkney JH**. Bariatric surgery to treat diabetes: A diabetologist's view

International Diabetes Federation, Montreal 2009 (Oral presentations)

K.Kos, S. Wong, D. Kerrigan, **J.H. Pinkney**, J.P.H. Wilding. The fibrosis promoter SPARC and its relation to the collagen-like adipokine adiponectin in human obesity.

K. Kos, S. Wong, D. Kerrigan, J.P.H. Wilding, **J.H. Pinkney**. Depot-specific expression of MMIF, MCP-1 and MIP-1alpha in human adipose tissue in relation to systemic inflammation

## FOCUS 2015

L Ghataore, J Tomlinson, DR Taylor, NF Taylor, K Bond, E Stenhouse, **J Pinkney**, RP Vincent. Steroid Metabolism in relation to Fat Distribution and Insulin Resistance in Polycystic Ovarian Syndrome

SJ Redding, RP Vincent, TK Dew, **J Pinkney**, J Tomlinson. Attenuated incretin response in Polycystic Ovary Syndrome

## European Association for the study of Diabetes, Stockholm, 2015

Tomlinson J, Mari A, Tura A, Bond K, Stenhouse E, Vincent RP, **Pinkney J**. The beta cell and insulin resistance in Polycystic Ovary Syndrome: New insights into the origins and prevention of type 2 diabetes.

**Pinkney J**, Mari A, Tura A, Bond K, Stenhouse E, Vincent RP, Tomlinson J. Insulin sensitivity with reactive hypoglycaemia: A metabolic subtype of Polycystic Ovary Syndrome associated with reduced risks of type 2 diabetes.

## University of Plymouth Methods Conference October 2015.

Dawn Swancutt, Sian Joel-Edgar, Mike Allen, Daniel Thomas, Heather Brant, Jonathan Benger, Richard Byng, **Jonathan Pinkney**. The 'Lean' approach of Value Stream Mapping in Emergency Care.

## Association of Physicians annual meeting, 2016.

**Pinkney J**, Rance S, Benger J, Joel-Edgar S, Swancutt D, Westlake D, Pearson M, Thomas D, Holme I, Endacott R, Anderson R, Allen M, Purdy S, Campbell J, Sheaff R and Byng R (The Avoidable Acute Admissions [3A] study investigators). How can hospitals safely reduce avoidable acute admissions of complex elderly patients? The 3A study.

## Association of Physicians annual meeting, 2016.

**Pinkney J**, Mari A, Tura A, Bond K, Stenhouse E, Royce V, Tomlinson J. The pancreatic beta cell, adiposity and insulin sensitivity in Polycystic Ovary Syndrome: Insights into the mechanisms of type 2 diabetes.

## Association of Physicians annual meeting, 2016.

**Pinkney J**, Streeter A, Jeffery A, Chynoweth J, Wilkin T, Hosking J. Early puberty and increased risk of cardiometabolic disease: Role of weight gain, Sex Hormone Binding Globulin and free androgen levels. **(Oral presentation)**.

European Association for the Study of Diabetes, Munich, 2016.

Jeffery S, Jeffery A, Hosking J, Murphy M, Wilkin T, **Pinkney J**. Gender Differences in Insulin Resistance during Adolescence: a Longitudinal Study.

2<sup>nd</sup> International Conference on Realist Evaluation and Synthesis.

Swancutt D, **Pinkney J et al**. Local workings of acute admission avoidance: a critical realist examination of resource deployment in four hospital emergency departments

European Society for Health and Medical Sociology, Geneva 2016

Debra Westlake, Susanna Rance, Heather Brant, Ingrid Holme, Catherine Pope, **Jonathan Pinkney**, Richard Byng. Talking carers into being: contested identities and roles of accompanying persons in emergency department decision-making.

Plymouth Hospitals NHS Trust Research Conference 2016 (**First Prize**)

How can hospitals safely reduce Avoidable Acute Admissions? Dawn Swancutt, Susanna Rance, Jonathan Bengner, Heather Brant, Sian Joel-Edgar, Debra Westlake, Mark Pearson, Daniel Thomas, Ingrid Holme, Ruth Endacott, Robert Anderson, Michael Allen, Sarah Purdy, John Campbell, Rod Sheaff, Richard Byng, **Jonathan Pinkney**.

**REFEREES: On request**